Mixed-Order Correlated Dual-Loop Sturdy MASH CT-ΔΣ Modulator With Distributed Signal Feed-In and VCO Quantizer ...

This awesome Half-Life 2 video mash-up trades Gordon Freeman for gun-toting action movie badass John Rambo.

Altimmune stock took a huge hit after its liver disease drug, pemvidutide, failed to show strong results in reducing fibrosis during a key MASH trial. While it helped with MASH resolution and weight ...

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed 53% in the aftermath of the readout.

Altimmune (ALT) stock plunges as a Phase 2b trial for its experimental MASH therapy shows mixed results. Read more here.

Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 liver disease study.

GAITHERSBURG, Md. - Altimmune, Inc. (NASDAQ:ALT), whose stock has surged over 13% in the past week according to InvestingPro data, announced Thursday that its Phase 2b trial of pemvidutide for ...

First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of ...

Efruxifermin Phase IIb Trial in MASH-Related Cirrhosis Shows Long-Term Potential Despite Early Miss The trial results, published by The New England Journal of Medicine (NEJM), did indicate encouraging ...

From the outset, the cast of the television series MASH was a solid ensemble of performers, led by Alan Alda, who consistently walked the show's tightrope between comedy and drama. Together, the ...

Home / Small Molecules / Rivus Pharmaceuticals Announces Positive Topline Results from Phase 2 M-ACCEL Trial of HU6 Showing Significant Reductions in Liver Fat in Patients with MASH ...